Analyst Price Target is $9.00
▲ +87.11% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for 2seventy bio in the last 3 months. The average price target is $9.00, with a high forecast of $18.00 and a low forecast of $2.00. The average price target represents a 87.11% upside from the last price of $4.81.
Current Consensus is
Moderate Buy
The current consensus among 9 contributing investment analysts is to moderate buy stock in 2seventy bio. This rating has held steady since May 2024, when it changed from a Hold consensus rating.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More